Mitochondria present in a human cell is responsible for converting food into energy in body. Mutations of mitochondrial DNA can lead to several illnesses that cause poor growth, muscle weakness, learning disabilities, increased risk of infection, respiratory problem and many more.
Mitochondrial disorders are rare and chronic affecting several body parts like nerves, heart, kidney, liver and pancreas. Some disorders caused due to excess mitochondrial DNA mutation are Leber’s hereditary optic neuropathy, Leigh syndrome, mitochondrial myopathy, mitochondrial DNA depletion syndrome and others.
According to the National Institute of Health (NIH), mitochondrial disease is a type of genetic disease with a minimum prevalence of greater than 1 in 5000 people across the globe.Covid-19 has led to lockdown in several countries delaying manufacturing activities in mitochondrial DNA market.
Ask for brochure of Market @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-12580
There has been observed supply chain disruption due to restrictions laid on trading across borders by various countries. The significant decline in hospital visits and the treatment-seeking rate will impact mitochondrial DNA market. Leading biopharmaceuticals are inclined towards developing coronavirus cure, delaying other clinical trials impact the growth rate of mitochondrial DNA market.
Mitochondrial DNA Market: Drivers and Restraints
The rise in the prevalence of mitochondrial disorders increases the demand for mitochondrial DNA market. Clinical stage development biopharmaceuticals attract investments from private players leading to an expansion of mitochondrial DNA market.
For instance, In June 2018, Stealth Biotherapeutics Corp. announced $100 million funds being raised from investors to develop and commercialize Elamipretide drug used as therapeutic for mitochondrial myopathy which is caused due to mutations in mitochondrial DNA.
Advancement in technology and research and development activities is expected to fuel mitochondrial DNA market growth. Lack of awareness about therapeutic options available for mitochondrial dysfunction is expected to hinder mitochondrial DNA market growth. The stringent regulatory requirement for drug approval is a challenging factor for mitochondrial DNA market growth.
Mitochondrial DNA Market: Overview
NSAIDs is expected to hold a major revenue share of mitochondrial DNA market during the forecast period. Therapeutic application is expected to dominate the mitochondrial DNA market during the forecast period with an increasing prevalence of mitochondrial disorders.
Diagnostic application in mitochondrial DNA market holds a significant share due to its ability to help detect cancer. Oral drugs are most common for mitochondrial DNA market. Whereas, hospital pharmacies is the largest distribution channel for mitochondrial DNA market. Increased adoption of e-commerce is will increase the demand for online pharmacies in mitochondrial DNA market.
Mitochondrial DNA Market: Region-wise Outlook
North America will continue to dominate the mitochondrial DNA market in the coming decade with a high rate of prevalence of mitochondrial disorders. The high rate of approvals and commercialization of pharmaceutical drugs increases the demand for mitochondrial DNA market in North America.
Europe is the second leading region in the mitochondrial DNA market with increased investments towards drug development and advanced technology. Asia-pacific is lucrative market with a higher growth rate in the mitochondrial DNA market during the forecast period with a large patient population in the region and increasing healthcare expenditure.
The Middle East and Africa are expected to observe the least growth in mitochondrial DNA market due to poor healthcare infrastructure and economic conditions in the region.
Mitochondrial DNA Market: Key Market Participants
Major players in mitochondrial DNA market include
- Pfizer Inc.
- Novartis AG
- Takeda Pharmaceuticals
- Amgen Inc.
- NeuroVive Pharmaceutical AB
- Entogene AG
- Stealth Biotherapeutics
- Ixchel Pharma
- Reata Pharmaceuticals
- Khondrion BV
- Alkeus Pharmaceuticals
- Intercept Pharmaceutics
The research report on mitochondrial DNA market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.
It also contains projections using a suitable set of assumptions and methodologies. The research report on mitochondrial DNA market provides analysis and information according to market segments such as drug class, route of administration, application, and region.
The report covers exhaust analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Europe (Germany, Italy, France, U.K, Spain, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, ASEAN)
- Oceania (Australia, New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Report Highlights:
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-12580
Mitochondrial DNA Market: Segmentation
drug type:
- Anti-inflammatory Biologics
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
application:
- Therapeutic
- Research and development
- Diagnostic
route of administration:
- Oral
- Intravenous
distribution channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies